ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America ...

A total of 378 patients were included in the study, 193 were female (51.1%), and the mean age of was 50.51 ± 14.72 for all patients (range 16–84). Two hundred and twenty six patients were in the IBS ...

The approval was based on data from two phase 3 induction studies and one phase 3 maintenance study. The Food and Drug Administration (FDA) has approved Rinvoq ® (upadacitinib) for the treatment of ...

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod ...

Merck & Co Inc. MRK on Monday said its investigational therapy tulisokibart achieved the primary endpoint in a Phase 3 study ...

Beerse, Belgium (28 February 2025) – Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

Share on Pinterest New research is testing the medication tulisokibart in treating ulcerative colitis. Maria Korneeva/Getty Images Ulcerative colitis is a type of inflammatory bowel disease (IBD) and ...

The U.S. Food and Drug Administration today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis. Xeljanz is the first oral medication ...

The appraisal committee considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

Background Irritable bowel syndrome (IBS) is a chronic functional bowel disorder. The frequency of microscopic colitis and focal active colitis in the colonic mucosa has been investigated in IBS ...